Opto

Opto is a subsidiary of Uni Pharma and Athroa Innovations. It serves as the partner of its two parent companies in the field of advanced diagnostic technologies. NanoSpot.ai is our first product, functioning as a technology platform that will subsequently enable testing for pathogens beyond SARS-CoV-2 as well as numerous other immunoassays, offering reliability, speed, and cost-effectiveness.